Skip to content

Study · Not a test of the peptide alone · 2009

3 results

Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.

Hassan K, Heptulla RA

Pediatric diabetes18 Dec 2008Cited by 14 (Europe PMC)

PMID19140902 (opens in a new tab)DOI10.1111/j.1399-5448.2008.00490.x (opens in a new tab)PepBankPUB-19140902
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome

    In adolescents with T1DM, premeal pramlintide plus reduced postmeal insulin lowered glucose AUC compared with the prescribed premeal insulin regimen.

    In plain wordsIn adolescents with T1DM, premeal pramlintide plus reduced postmeal insulin lowered glucose exposure compared with the prescribed premeal insulin regimen.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose AUC
    Study

    n = 8

    Comparator
    Prescribed premeal insulin regimen
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glucose AUC
    6600 mg/dL/min
    pramlintide plus postmeal insulin
    Glucose AUC
    20,230 mg/dL/min
    prescribed premeal insulin

    Source sentences

    Summary
    Postprandial incremental BG for the duration of the study was reduced in study B vs. study A with AUC((-60 to 300 min)) (area under the curve) at 6600 +/- 2371 vs. 20 230 +/- 3126 mg/dL/min (367 +/- 132 vs. 1124 +/- 174 mmol/L/min) (p < 0.001).
    2 context sentences
    Summary · context
    Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin).
    Summary · context
    Prandial insulin dose for study B was decreased by 20% and given postmeal, while pramlintide was given just before the meal.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome

    In adolescents with T1DM, glucagon was suppressed after premeal pramlintide and postmeal insulin.

    In plain wordsIn adolescents with T1DM, glucagon was suppressed after premeal pramlintide and postmeal insulin.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGlucagon suppression
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Duration of glucagon suppression
    ≈ 120 min
    after 30 microg pramlintide and postmeal insulin

    Source sentences

    Summary
    Glucagon concentration was suppressed for approximately 120 min following administration of 30 microg of pramlintide and postmeal insulin (p < 0.003).
    2 context sentences
    Summary · context
    Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin).
    Summary · context
    Prandial insulin dose for study B was decreased by 20% and given postmeal, while pramlintide was given just before the meal.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 03HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialSafety outcome

    In adolescents with T1DM, no severe hypoglycemic episodes occurred in the study of premeal pramlintide and postmeal insulin.

    In plain wordsIn adolescents with T1DM, no severe low blood sugar episodes occurred in the study of premeal pramlintide and postmeal insulin.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSevere hypoglycemia
    Study

    n = 8

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    No severe hypoglycemic episodes were experienced in this study.
    2 context sentences
    Summary · context
    Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin).
    Summary · context
    Prandial insulin dose for study B was decreased by 20% and given postmeal, while pramlintide was given just before the meal.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00442767

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Montefiore Medical Centern = 8Feb 2007 to Feb 2009

Type 1 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 10 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.